Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
ETFs with RCPT as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.5%||ALPS Medical Breakthroughs ETF (SBIO)||+7.56 (25.33%)|
|1.53%||PowerShares DWA SmallCap Momentum Portfolio (DWAS)||+1.62 (4.01%)|
|0.9%||iShares Morningstar Small-Cap ETF (JKJ)||-0.50 (-0.36%)|
|0.86%||iShares Microcap ETF (IWC)||+0.01 (0.01%)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disorders. Our product candidates span three distinct specialty disease areas. We are developing our lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). We are developing our second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which we have been granted Orphan drug designation. Our strategy is to develop best-in-class drug candidates and selectively pursue first-in-class market positions. The mechanism of action for each of our product candidates has been validated in one or more immunology indications. Ozanimod was selected for pharmaceutic properties with potential to demonstrate best-in-class differentiation in RMS. ... More ...
Where does RCPT fit in the risk graph?
|Annual EPS Est:||$-4.63|
|Quarterly EPS Est:||-1.29|